Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-Cis-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission | Zendy

NaiKong V. Cheung | Zendy; Irene Y. Cheung | Zendy; Brian H. Kushner | Zendy; Irina Ostrovnaya | Zendy; Elizabeth Chamberlain | Zendy; Kim Kramer | Zendy; Shakeel Modak | Zendy

Open Access

Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-Cis-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission

Author(s) -

NaiKong V. Cheung,

Irene Y. Cheung,

Brian H. Kushner,

Irina Ostrovnaya,

Elizabeth Chamberlain,

Kim Kramer,

Shakeel Modak

Publication year - 2012

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2011.41.3807

Subject(s) - medicine , regimen , oncology , neuroblastoma , gastroenterology , immunology , biology , genetics , cell culture

Anti-GD2 monoclonal antibody (MoAb) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) has shown efficacy against neuroblastoma (NB). Prognostic variables that could influence clinical outcome were explored.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research